Catherine Sharbaugh
Family · Long Island City, NYNPI 1689858912
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 63.3% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2021 at $15,070 and has fallen 85.7% since, to $2,158 in 2025. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $275.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$15K
- Otsuka America Pharmaceutical, Inc.$1K
- Modernatx, Inc.$788
- Gilead$604
- Novo Nordisk$595
- AstraZeneca$466
- plus $5K from 24 others
What the payments were for
- Consulting fees$7883%
- Speaking & faculty fees$10,84547%
- Travel & lodging$2,93213%
- Food & beverage$8,56037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 19 | $14,632 |
| Otsuka America Pharmaceutical, Inc. | 9 | $1,141 |
| Modernatx, Inc. | 1 | $788 |
| Gilead | 5 | $604 |
| Novo Nordisk | 6 | $595 |
| AstraZeneca(2 entities) | 4 | $466 |
| Sage Therapeutics, LLC | 4 | $456 |
| AbbVie | 3 | $399 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $396 |
| Teva Pharmaceuticals USA, Inc. | 3 | $374 |
| Mylan Specialty L.p. | 3 | $373 |
| Sumitomo Pharma America, Inc. | 2 | $300 |
| Neurocrine Biosciences, Inc. | 2 | $253 |
| Boehringer Ingelheim | 2 | $247 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $242 |
| Biohaven Pharmaceuticals, Inc. | 2 | $220 |
| Madrigal Pharmaceuticals | 1 | $150 |
| Ultragenyx Pharmaceutical Inc. | 1 | $148 |
| Biomerieux Inc | 1 | $142 |
| Phathom Pharmaceuticals, Inc. | 1 | $130 |
| E.r. Squibb & Sons, L.L.C. | 1 | $129 |
| Impel Pharmaceuticals Inc. | 1 | $127 |
| Calliditas Therapeutics US Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $123 |
| Viiv Healthcare Company | 1 | $122 |
| Scpharmaceuticals Inc. | 1 | $122 |
| Amgen | 1 | $112 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Lilly USA, LLC | 1 | $80 |
| Neurelis, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xofluza$14,484
- Moderna Covid-19 Vaccine$788
- ABILIFY MAINTENA$550
- ABILIFY ASIMTUFII$550
- REXULTI$500
- Yupelri$373
- MYFEMBREE$300
- INGREZZA$253
- UZEDY$249
- Vemlidy$242
- Entyvio$242
- NURTEC ODT$220
- BOTOX$150
- REZDIFFRA$150
- XOLAIR$148
- CRYSVITA$148
- BIOFIRE RESPIRATORY PANEL 2.1$142
- VOQUEZNA$130
- COBENFY$129
- Trudhesa$127
How this compares
$23,125 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Other family in Long Island City
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.